<DOC>
	<DOCNO>NCT01832532</DOCNO>
	<brief_summary>This open label , control study . The investigator study FDA approve diabetes medicine liraglutide ( Victoza® ) improve sleep apnea adult . This study test liraglutide 20 adult without diabetes diagnose sleep apnea.The treatment group compare control group 10 adult without diabetes sleep apnea use liraglutide . Both group continue receive standard care sleep apnea prescribe manage sleep physician throughout study participation . Everyone study two study visit one overnight sleep study research . Subjects recent sleep study otherwise qualify study , additional research sleep study determine baseline severity sleep apnea . The study visit include fast blood sample breathe test ( pulmonary function test hypercapnic challenge ) . There weekly phone visit include questionnaire sleepiness . The group take liraglutide check blood sugar two time day medicine .</brief_summary>
	<brief_title>A Pilot Study Effects Sleep Disordered Breathing ( SDB ) When Using Drug Liraglutide 4 Weeks</brief_title>
	<detailed_description>This pilot study aim measure change obstructive apnea/hypopnea index non-diabetic patient treat first time glucagon-like peptide-1 ( GLP-1 ) agonist , Liraglutide . Sleep disorder breathing ( SDB ) consist nocturnal alveolar hypoventilation / obstructive sleep apnea result abnormality upper airway tone ventilation sleep . The development new pharmacological treatment sleep disorder breathing ( SDB ) could bring breakthrough discovery impact rapidly grow population child adult disorder . The investigator hypothesize GLP-1 play central role improvement SDB administration GLP-1 receptor agonist patient OSA correct improve SDB . - Hypothesis 1 : Administration Liraglutide patient severe OSA define apnea hypopnea index ≥ 8 /hr . result mean reduction index minimum 50 % 4 week . - Hypothesis 2 : Administration Liraglutide result significant increase Orexin level , decrease leptin , decrease Epworth Sleepiness Scale ( ESS ) score increase carbon dioxide ( CO2 ) chemosensitivity . This open label , non-randomized , control pilot study . Subjects heavy obese non-diabetic adult diagnose sleep apnea . 20 subject treat liraglutide 4 week compare 10 untreated control . Study time point baseline 4 week post treatment . Study procedure include pre post treatment : fasting blood glucose , hemoglobin A1C ( HbA1C ) , Orexin leptin ; ESS questionnaire ; pulmonary function test hypercapnic challenge . The procedure also include post treatment overnight research sleep study measure change apnea index diagnostic sleep study do previous study enrollment need , baseline research sleep study .</detailed_description>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Age 1860 year Diagnosis severe obstructive sleep apnea ( OSA ) AHI ≥ 8 /hour sleep Ability willingness comply protocol procedure e.g . correct handle trial product , compliance visit schedule BMI ≥ 27 For Cohort 1 : If female childbearing capacity , willing use acceptable birth control use study drug A major medical condition renal hepatic failure Treatment glucagonlike peptide1 ( GLP1 ) receptor agonist , dipeptidyl peptidase4 inhibitor insulin within last 3 month prior screen Diagnosis type 1 type 2 diabetes per judgment investigator BMI &lt; 27 History glycosylated hemoglobin ( HbA1c ) equal 6.5 % Significant craniofacial abnormality may cause OSA Respiratory neuromuscular disease could interfere result trial opinion investigator Use central stimulant , hypnotic , mirtazepine , opioids , trazodone drug incretin family within previous 3 month prior screen Previous surgical treatment obesity Familial personal history Multiple Endocrine Neoplasia type 2 familial Medullary Thyroid Carcinoma Personal immediate family history thyroid cancer History chronic pancreatitis idiopathic acute pancreatitis History Major Depressive Disorder suicide attempt Systolic blood pressure equal 160 mmHg and/or diastolic blood pressure equal 100 mmHg History alcoholism Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Sleep Apnea</keyword>
	<keyword>Sleep Disordered Breathing</keyword>
	<keyword>liraglutide</keyword>
	<keyword>glucagon-like peptide-1 agonist</keyword>
	<keyword>Orexin</keyword>
	<keyword>leptin ,</keyword>
</DOC>